Capsugel Completes Acquisitions of Xcelience and Powdersize
News Jan 07, 2016
Capsugel has announced that it has completed its acquisitions of Xcelience and Powdersize. Xcelience and Powdersize are now part of Capsugel's Dosage Form Solutions business unit, which partners with pharmaceutical and health and nutrition customers around the world to advance products through an integrated approach to the design, development and manufacture of high-quality, innovative dosage forms.
The acquisitions, announced on December 14, 2015, provide Capsugel with specialized clinical trial manufacturing and supply capabilities for a broad range of solid dosage forms; development and manufacturing for specialized products such as highly potent and controlled substance compounds; and micronization capabilities that augment the company's existing formulation design services and premier bioavailability enhancement technology platform.
When combined with Capsugel’s wide array of industry-leading hard capsule technologies, the expanded capabilities of Capsugel Dosage Form Solutions make the company better positioned than ever to partner with customers to deliver innovative, patient-centric dosage forms and solutions.
A form of the hallucinogenic party drug ketamine has cleared one of the final hurdles toward clinical use as an antidepressant. During a meeting at the US Food and Drug Administration (FDA) in Silver Spring, Maryland, an independent advisory panel voted 14-2 in favor of recommending a compound known as esketamine for use in treating depression.READ MORE